Gustavo Morales, MD
Clinical Cardiac Electrophysiology · Birmingham, ALNPI 1023202306
Payments from drug & device makers
Across 764 payments — averaging $834.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$337K
- Volta Medical Inc$92K
- Biosense Webster, Inc.$78K
- Medical Device Business Services, Inc.$62K
- Boston Scientific$35K
- Medtronic$31K
- plus $3K from 23 others
What the payments were for
- Consulting fees$117,81169%
- Speaking & faculty fees$32,81319%
- Travel & lodging$6,1524%
- Food & beverage$14,4208%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 177 | $337,086 |
| Volta Medical Inc | 26 | $91,914 |
| Biosense Webster, Inc. | 256 | $78,155 |
| Medical Device Business Services, Inc. | 37 | $61,772 |
| Boston Scientific | 73 | $34,549 |
| Medtronic(2 entities) | 53 | $30,966 |
| Novartis | 50 | $706 |
| Acutus Medical, Inc. | 6 | $573 |
| Johnson & Johnson(2 entities) | 8 | $377 |
| Pfizer | 11 | $203 |
| Atricure, Inc. | 2 | $180 |
| E.r. Squibb & Sons, L.L.C. | 9 | $155 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $154 |
| Sanofi-aventis U.S. LLC | 8 | $136 |
| Impulse Dynamics (USA) Inc. | 7 | $130 |
| Amgen | 6 | $81 |
| Boehringer Ingelheim | 5 | $81 |
| Merck | 4 | $73 |
| Irhythm Technologies, Inc. | 4 | $70 |
| AbbVie | 1 | $57 |
| Elutia, Inc. | 3 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Philips North America LLC | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Inari Medical, Inc. | 1 | $21 |
| Bayer | 1 | $19 |
| Astellas Pharma US Inc | 1 | $16 |
| GSK | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$113,772
- WATCHMAN Access System$21,838
- GENERAL TACHY$4,500
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$3,250
- Carto 3 System$3,225
- ENSITE$2,859
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,500
- AVEIR$1,525
- GENERAL VASCULAR ACCESS$1,250
- GENERAL BRADY$1,000
- EMBLEM$886
- EMBLEM MRI S-ICD$500
- Micra$469
- Arctic Front$406
- Advisor Catheter$300
- VX1$279
- XARELTO$229
- Watchman$223
- EPI-SENSE GUIDED COAGULATION SYS$164
- QUARTET$160
How this compares
$637,640 in reported general payments places this provider in the 85th percentile of 42 clinical cardiac electrophysiology providers in Alabama.
See all clinical cardiac electrophysiology providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 483 | $461,739 |
| XareltoRivaroxaban | 106 | $97,639 |
| MultaqDronedarone Hcl | 37 | $51,775 |
| EntrestoSacubitril/Valsartan | 59 | $42,752 |
| Flecainide Acetate | 111 | $8,871 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 19 | $3,930 |
| Amiodarone Hcl | 69 | $2,527 |
| Metoprolol Succinate | 161 | $1,910 |
| SotalolSotalol Hcl | 57 | $1,676 |
| Dofetilide | 19 | $1,435 |
| Valsartan | 25 | $1,237 |
| Propafenone Hcl ErPropafenone Hcl | 12 | $814 |
| Losartan Potassium | 69 | $781 |
| Carvedilol | 77 | $758 |
| Potassium Chloride | 23 | $623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $203 | $461,739483 claims |
| Johnson & JohnsonXarelto | $377 | $97,639106 claims |
| Sanofi-aventis U.S. LLCMultaq | $136 | $51,77537 claims |
| NovartisEntresto | $706 | $42,75259 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 42 clinical cardiac electrophysiology providers in Alabama.
Other clinical cardiac electrophysiology in Birmingham
- Hugh McElderryBirmingham$1.9M
- Anil RajendraBirmingham$1.9M
- Byron ColleyBirmingham$1.3M
- William MaddoxBirmingham$615K
- Harish DoppalapudiBirmingham$104K
- Francis BennBirmingham$95K
- Terence DunnBirmingham$73K
- Ruchit ShahBirmingham$72K
- Ibrahim HannaBirmingham$59K
- Macy SmithBirmingham$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.